Rhinomed Limited announced appointment of AntiMicrobial Technologies Group (AMT Group Australia Pty Ltd) as a distributor of Rhinoswab in Australia and BioTrading Benelux BV as a distributor in Belgium, the Netherlands and Luxembourg (Benelux). Rhinomed announced that it has appointed AMT Group Australia Pty Ltd. and BioTrading Benelux BV as distributors of the Rhinoswab and Rhinoswab Junior. The distribution agreement with AMT Group Australia Pty Ltd. is for an initial term of 12 months and provides AMTG the non-exclusive right to sell the Rhinoswab in Australia. The agreement is effective as of 19 August 2021. The distribution agreement with BioTrading Benelux BV is for an initial three year term. BioTrading Benelux BV has been granted an exclusive right to sell the Rhinoswab in Belgium, the Netherlands and Luxembourg. BioTrading Benelux BV serves the biotechnology, pharmaceutical and clinical industries (https://biotrading.com). The agreement is effective as of 31 August 2021. The agreements provide the distributor the right to sell the Rhinoswab in the territories, but does not inhibit Rhinomed's ability to sell or supply the Rhinoswab to Rapid antigen testing companies competing in those markets. Other terms of the distribution agreements are standard for agreements of this nature.